Are you interested in Preference studies? You have heard about DCE, but not sure whether this approach is the most appropriate for you? You want to know how to define such a project and understand outcomes you would expect from?

On June 25th, 2021 our DCE webinar took place.

A Preference study is a must have for any patient-centric organization when decisions have to be made to drive a product development and ensure it meets patients’ expectations.

Among the different approaches possible, the Discrete Choice Experiment is now recognized as a gold standard and yet, few projects using this methodology have been shared.

This webinar, organized by Xtalks, showed:

• The definition of DCE
• What is the value of DCE
• Best practices implementation How to build a preference study using DCE

Access the replay

About the speakers

This live session was hosted by Lise Radoszycki Chief Operating Officer at Carenity and Nawal Bent-Ennakhil Lead Epidemiologist at Takeda.

Lise is Carenity’s Chief Operating Officer – Now part of the EvidentIQ Group. She oversees and coordinates the actions of the Data Science team which produces real-life studies, along with all digital projects and strategy to grow and engage the platform’s communities. She co-chairs Carenity’s Science and Ethics Committee.

Lise Radoszycki is a Method and Models statistic engineer with a degree from INSA (National Institute of Applied Sciences) in Toulouse, France. She also studied at the Universidad de Guadalajara (Mexico). She’s an active member of AFCRO (French CRO Association) and participates in the European think-tank Health Data Institute.

Nawal is Lead Epidemiologist at Takeda. Nawal is an epidemiologist by training. She has been leading Real World Evidence projects for more than 10 years now. She held several positions within HEOR and RWE teams and she is now lead Epidemiologist at Takeda EUCAN. Nawal has been closely managing the DCE-Preference Study Project with Carenity.

She will share her experience of collaborating with Carenity on such a project. She will explain why the DCE methodology has been chosen, what were the challenges of such methodology, how Carenity’s Team support Takeda EUCAN with the methodology its deployment and analysis of the results, what have been the main learnings of this methodology and how results will be used by Takeda EUCAN.

Contact us for more information: pro@carenity.com

Number of vaccine refusers highest in France, lowest in the UK

Hamburg, 12.05.2021: Data science group EvidentIQ, with its subsidiary company Carenity, has published a survey with 3,353 participants on the situation of chronic patients during the pandemic. The target group included adults from France, the UK, Germany, Italy and the US. Among other findings regarding the number of canceled medical visits and procedures, or the rise of telehealth services, the difference in preparedness for vaccination per country stood out.

The motivation to get vaccinated does not come as a surprise. 48 percent state they are at risk, 46 percent want to protect others and 41 percent simply want to protect themselves from the virus. Only 18 percent indicate it would be easier to travel when vaccinated. The most frequent chronic conditions among the respondents are Type 2 diabetes (24%), asthma (19%), multiple sclerosis (15%) and COPD (14%). Given the severity of these illnesses, it is surprising that a mere 67 percent in France and 47 percent in Germany do not intend to get vaccinated.

Michael Chekroun, Chief Strategy and Transformation Officer of the EvidentIQ group and Founder of Carenity explains these results:

“When it comes to the COVID-19 vaccines, nearly half of our respondents are afraid of side effects. Another 45 percent name the lack of information as reason for their reluctance to be vaccinated. To some extent this is understandable.”

Chekroun refers to the comparably short development and trial phases of the new vaccines. For these highly regulated trial processes imposed by public entities like EMA and FDA – EvidentIQ provides software infrastructure, scientific services and even access to patients to secure and automate testing procedures.

“Many people are not aware that for extraordinary situations like these there have always been Accelerated Approval Programs to shorten time-to-market for a new treatment. This is obviously where chronic patients are understandably nervous, fearing side effects and requiring more information. Our survey shows that only 4 percent of all respondents generally oppose vaccination.”

Also, the survey shows that 46 percent report that medical visits or procedures have been canceled or postponed in the first wave of COVID-19, while 75 percent report the same for wave 2.

This may explain why roughly 67 percent of patients in the US are open to the use of telehealth consultations, in Europe only 47 percent.

Read the the full interview with Michael Chekroun on the outcome of this survey and get a free copy of the complete results.

Contact us for more information.